NYLIM
LGND icon

New York Life Investment Management’s Ligand Pharmaceuticals LGND Stock Holding History

New York Life Investment Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-5,195
Closed -$380K – 1123
2024
Q1 		$380K Buy
5,195
+464
+10% +$34.2K ﹤0.01% 849
2023
Q4 		$338K Sell
4,731
-110
-2% -$6.49K ﹤0.01% 1142
2023
Q3 		$290K Sell
4,841
-761
-14% -$50.1K ﹤0.01% 1176
2023
Q2 		$404K Sell
5,602
-949
-14% -$71.2K ﹤0.01% 988
2023
Q1 		$482K Buy
+6,551
New +$466K 0.01% 864

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $838M AUM 14.24% 1-Year Est. Return

New York Life Investment Management's LGND Position: Q2 2024 in Review

New York Life Investment Management sold out of Ligand Pharmaceuticals (LGND) in Q2 2024, closing a stake of 5,195 shares — an estimated $380K sold.

New York Life Investment Management first reported a position in LGND in Q1 2023 and held it in 5 quarters. The position peaked at $482K in Q1 2023. 234 funds tracked by Wall St. Rank hold LGND as of Q2 2024.

  • New York Life Investment Management reported no remaining Ligand Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • New York Life Investment Management sold 5,195 Ligand Pharmaceuticals shares in Q2 2024, an estimated $380K.
  • New York Life Investment Management first reported a position in Ligand Pharmaceuticals in Q1 2023 and held it in 5 quarters.
  • New York Life Investment Management's Ligand Pharmaceuticals position peaked at $482K in Q1 2023.
  • 234 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2024.

Based on New York Life Investment Management's 13F filing for Q2 2024, filed 5 Aug 2024.